Literature DB >> 26493647

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

David D Bowtell1, Steffen Böhm2, Ahmed A Ahmed3, Paul-Joseph Aspuria4, Robert C Bast5, Valerie Beral6, Jonathan S Berek7, Michael J Birrer8, Sarah Blagden9, Michael A Bookman10, James D Brenton11, Katherine B Chiappinelli12, Filipe Correia Martins11, George Coukos13, Ronny Drapkin14, Richard Edmondson15, Christina Fotopoulou9, Hani Gabra9, Jérôme Galon16, Charlie Gourley17, Valerie Heong18, David G Huntsman19, Marcin Iwanicki20, Beth Y Karlan4, Allyson Kaye21, Ernst Lengyel22, Douglas A Levine23, Karen H Lu5, Iain A McNeish24, Usha Menon25, Steven A Narod26, Brad H Nelson27, Kenneth P Nephew28, Paul Pharoah29, Daniel J Powell30, Pilar Ramos31, Iris L Romero22, Clare L Scott18, Anil K Sood5, Euan A Stronach9, Frances R Balkwill2.   

Abstract

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

Entities:  

Mesh：

Year:  2015        PMID： 26493647      PMCID： PMC4892184          DOI： 10.1038/nrc4019

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  181 in total

1.  Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Authors:  Gottfried E Konecny; Chen Wang; Habib Hamidi; Boris Winterhoff; Kimberly R Kalli; Judy Dering; Charles Ginther; Hsiao-Wang Chen; Sean Dowdy; William Cliby; Bobbie Gostout; Karl C Podratz; Gary Keeney; He-Jing Wang; Lynn C Hartmann; Dennis J Slamon; Ellen L Goode
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

2.  Mutations in BRIP1 confer high risk of ovarian cancer.

Authors:  Thorunn Rafnar; Daniel F Gudbjartsson; Patrick Sulem; Aslaug Jonasdottir; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Soren Besenbacher; Pär Lundin; Simon N Stacey; Julius Gudmundsson; Olafur T Magnusson; Louise le Roux; Gudbjorg Orlygsdottir; Hafdis T Helgadottir; Hrefna Johannsdottir; Arnaldur Gylfason; Laufey Tryggvadottir; Jon G Jonasson; Ana de Juan; Eugenia Ortega; Jose M Ramon-Cajal; Maria D García-Prats; Carlos Mayordomo; Angeles Panadero; Fernando Rivera; Katja K H Aben; Anne M van Altena; Leon F A G Massuger; Mervi Aavikko; Paula M Kujala; Synnöve Staff; Lauri A Aaltonen; Kristrun Olafsdottir; Johannes Bjornsson; Augustine Kong; Anna Salvarsdottir; Hafsteinn Saemundsson; Karl Olafsson; Kristrun R Benediktsdottir; Jeffrey Gulcher; Gisli Masson; Lambertus A Kiemeney; Jose I Mayordomo; Unnur Thorsteinsdottir; Kari Stefansson
Journal:  Nat Genet       Date:  2011-10-02       Impact factor: 38.330

3.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Authors:  Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 4.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

5.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Authors:  Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg
Journal:  Nat Genet       Date:  2010-04-18       Impact factor: 38.330

6.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

7.  Multiplexed ion beam imaging of human breast tumors.

Authors:  Michael Angelo; Sean C Bendall; Rachel Finck; Matthew B Hale; Chuck Hitzman; Alexander D Borowsky; Richard M Levenson; John B Lowe; Scot D Liu; Shuchun Zhao; Yasodha Natkunam; Garry P Nolan
Journal:  Nat Med       Date:  2014-03-02       Impact factor: 53.440

8.  Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.

Authors:  Joshy George; Kathryn Alsop; Dariush Etemadmoghadam; Heather Hondow; Thomas Mikeska; Alexander Dobrovic; Anna deFazio; Gordon K Smyth; Douglas A Levine; Gillian Mitchell; David D Bowtell
Journal:  Clin Cancer Res       Date:  2013-04-30       Impact factor: 12.531

9.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

10.  Biomarkers, the molecular gaze and the transformation of cancer survivorship.

Authors:  Kirsten Bell
Journal:  Biosocieties       Date:  2013-06
View more
  377 in total

1.  IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.

Authors:  Yinu Wang; Xingyue Zong; Sumegha Mitra; Anirban Kumar Mitra; Daniela Matei; Kenneth P Nephew
Journal:  JCI Insight       Date:  2018-12-06

2.  Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Authors:  Robert Cornelison; Zachary C Dobbin; Ashwini A Katre; Dae Hoon Jeong; Yinfeng Zhang; Dongquan Chen; Yuliya Petrova; Danielle C Llaneza; Adam D Steg; Laura Parsons; David A Schneider; Charles N Landen
Journal:  Clin Cancer Res       Date:  2017-08-04       Impact factor: 12.531

3.  Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study.

Authors:  He Zhang; Yunfei Mao; Xiaojun Chen; Guoqing Wu; Xuefen Liu; Peng Zhang; Yu Bai; Pengcong Lu; Weigen Yao; Yuanyuan Wang; Jinhua Yu; Guofu Zhang
Journal:  Eur Radiol       Date:  2019-04-08       Impact factor: 5.315

4.  Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials.

Authors:  Hong Song; Guo-Hui Cai; Jian Liang; Di-Shu Ao; Huan Wang; Ze-Hong Yang
Journal:  J Nanobiotechnology       Date:  2020-06-11       Impact factor: 10.435

5.  Targeting progesterone signaling prevents metastatic ovarian cancer.

Authors:  Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2020-12-01       Impact factor: 11.205

Review 6.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

7.  Small molecule inhibition of the CBFβ/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.

Authors:  Anne L Carlton; Anuradha Illendula; Yan Gao; Danielle C Llaneza; Adam Boulton; Anant Shah; Roger A Rajewski; Charles N Landen; David Wotton; John H Bushweller
Journal:  Gynecol Oncol       Date:  2018-03-16       Impact factor: 5.482

8.  High expression of integrin αvβ3 enables uptake of targeted fluorescent probes into ovarian cancer cells and tumors.

Authors:  Scott K Shaw; Cynthia L Schreiber; Felicia M Roland; Paul M Battles; Seamus P Brennan; Simon J Padanilam; Bradley D Smith
Journal:  Bioorg Med Chem       Date:  2018-03-06       Impact factor: 3.641

9.  MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc.

Authors:  Eleni Anastasiadou; Elena Messina; Tiziana Sanavia; Lucia Mundo; Federica Farinella; Stefano Lazzi; Francesca Megiorni; Simona Ceccarelli; Paola Pontecorvi; Francesco Marampon; Cira Rosaria Tiziana Di Gioia; Giorgia Perniola; Pierluigi Benedetti Panici; Lorenzo Leoncini; Pankaj Trivedi; Andrea Lenzi; Cinzia Marchese
Journal:  Cells       Date:  2021-03-01       Impact factor: 6.600

10.  Bitter taste receptors are expressed in human epithelial ovarian and prostate cancers cells and noscapine stimulation impacts cell survival.

Authors:  Louis T P Martin; Mark W Nachtigal; Tamara Selman; Elaine Nguyen; Jayme Salsman; Graham Dellaire; Denis J Dupré
Journal:  Mol Cell Biochem       Date:  2018-10-22       Impact factor: 3.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.